Premium
Iron chelators inhibit human platelet aggregation, thromboxane A 2 synthesis and lipoxygenase activity
Author(s) -
Barradas Manuel A.,
Jeremy Jamie Y.,
Kontoghiorghes George J.,
Mikhailidis Dimitri P.,
Hoflbrand A.Victor,
Dandona Paresh
Publication year - 1989
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/0014-5793(89)80201-7
Subject(s) - lipoxygenase , platelet , cyclooxygenase , chemistry , biochemistry , enzyme , in vitro , chelation , thromboxane a2 , pharmacology , thromboxane , immunology , receptor , medicine , organic chemistry
The iron chelators desferrioxamine and 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one (L1) inhibited human platelet aggregation in vitro as well as thromboxane A 2 synthesis and conversion of arachidonate to lipoxygenase‐derived products. Non‐chelating compounds related to L1 were without effect on cyclooxygenase or lipoxygenase activity. Since both cyclooxygenase and lipoxygenase are iron‐containing enzymes, it is suggested that the inhibition of platelet function by these iron chelators may be related to the removal or binding of iron associated with these enzymes. These iron chelators may therefore be of potential therapeutic value as platelet antiaggregatory agents and of possible use in the treatment of atherosclerotic and inflammatory joint diseases.